GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » ROE % Adjusted to Book Value

Cynata Therapeutics (ASX:CYP) ROE % Adjusted to Book Value : -34.04% (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics ROE % Adjusted to Book Value?

Cynata Therapeutics's ROE % for the quarter that ended in Dec. 2023 was -62.63%. Cynata Therapeutics's PB Ratio for the quarter that ended in Dec. 2023 was 1.84. Cynata Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -34.04%.


Cynata Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Cynata Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics ROE % Adjusted to Book Value Chart

Cynata Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.54 -6.17 -13.35 -9.63 -52.37

Cynata Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -15.41 -21.29 -75.96 -34.04

Competitive Comparison of Cynata Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Cynata Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynata Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's ROE % Adjusted to Book Value falls into.



Cynata Therapeutics ROE % Adjusted to Book Value Calculation

Cynata Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-70.17% / 1.34
=-52.37%

Cynata Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.63% / 1.84
=-34.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynata Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynata Therapeutics (ASX:CYP) Business Description

Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines